Although major guidelines uniformly recommend iron supplementation and erythropoietin stimulating agents (ESAs) for managing chronic anemia in persons with CKD [3–5], there are differences in the recommended Hb treatment target. This evidence concerns the gene GSTM1 and chronic kidney disease.